• Tivic Health Systems will rebrand as Valion Bio.
• Nasdaq ticker will change to VBIO from TIVC.
• Rebrand aligns with shift to late-stage biopharmaceutical focus centered on Entolimod, a candidate for Acute Radiation Syndrome under FDA Animal Rule pathway.
• Program targets potential BARDA-backed procurement for U.S. Strategic National Stockpile, positioned as non-dilutive revenue opportunity.
• Velocity Bioworks unit, acquired for about $16.3 million, is positioned to support Entolimod supply while building third-party CDMO revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604231605PR_NEWS_USPR_____CL42431) on April 23, 2026, and is solely responsible for the information contained therein.